EMA regular press briefing on COVID-19

Table of contents

Date: 28/05/2021
Location: Virtual meeting

Event summary

The European Medicines Agency (EMA) is holding a press briefing to provide an update on its most recent activities in the context of the COVID-19 pandemic. The briefing will also cover the outcome of the extraordinary meeting of EMA’s human medicine committee CHMP on Friday, 28 May 2021, to discuss the paediatric indication for Comirnaty.

Speakers:

  • Marco Cavaleri (Head of Biological Health Threats and Vaccines Strategy)
  • Fergus Sweeney (Head of Clinical Studies and Manufacturing Task Force).
  • Georgy Genov (Head of Pharmacovigilance)

The press briefing will be moderated by Marie-Agnes Heine (Head of Communication Department).

Virtual briefings for the media will now be organised on a regular basis, initially every two weeks. As a complement to these regular technical briefings, EMA will still organise ad-hoc press conferences as necessary and appropriate.

The press briefing will be held in English. No translations will be provided.

Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to the European Medicines Agency instead.

Order